# Myeloablative Conditioning Orca-T & Allogeneic Donor-Derived CD19/CD22-CAR TCells in B-Cell ALL

> **NCT05507827** · PHASE1 · ACTIVE_NOT_RECRUITING · sponsor: **Stanford University** · enrollment: 22 (actual)

## Conditions studied

- Lymphoid Leukemia

## Interventions

- **DRUG:** Allogeneic donor-derived T-cells transduced with bivalent lentiviral vector (CD19/CD22-BBz) chimeric antigen receptor (CAR)
- **DRUG:** Treg CD34+HSPC (Orca-T)

## Key facts

- **NCT ID:** NCT05507827
- **Lead sponsor:** Stanford University
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2022-08-18
- **Primary completion:** 2026-05
- **Final completion:** 2026-05
- **Target enrollment:** 22 (ACTUAL)
- **Last updated:** 2025-09-16

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05507827

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05507827, "Myeloablative Conditioning Orca-T & Allogeneic Donor-Derived CD19/CD22-CAR TCells in B-Cell ALL". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT05507827. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*